Acasti Pharma Completes Enrollment in GTX-104 Phase 3 Trial
PRINCETON, N.J. — Acasti Pharma Inc. (NASDAQ: ACST), a late-stage biopharmaceutical company that specializes in innovative solutions for unmet medical needs, has successfully finished enrolling patients in its key Phase 3 STRIVE-ON safety trial. This trial focuses on GTX-104, a novel injectable formulation of nimodipine aimed at treating aneurysmal subarachnoid hemorrhage (aSAH), a serious neurological condition.
Importance of the STRIVE-ON Trial
The STRIVE-ON trial marks a key achievement for Acasti as it seeks to evaluate the safety of GTX-104 in comparison to the traditional oral nimodipine treatment. This trial uses a randomized, open-label design, with 100 patients participating across about 25 hospitals throughout the U.S. Prashant Kohli, the CEO of Acasti, shared his enthusiasm for reaching this milestone sooner than expected, highlighting the commitment of the team and the support from clinical investigators. The trial's primary aim is to assess safety by monitoring adverse events such as hypotension among the patient groups involved.
What is Aneurysmal Subarachnoid Hemorrhage (aSAH)?
Aneurysmal subarachnoid hemorrhage occurs when an aneurysm ruptures, causing blood to cover the surface of the brain, which critically affects survival and recovery outcomes. Alarmingly, nearly 70% of patients who experience aSAH either die or become severely dependent afterward, with over 30% not surviving the first month following the hemorrhage.
In the U.S. alone, around 50,000 people are diagnosed with aSAH each year. Europe sees about 60,000 cases annually, while roughly 150,000 occurrences are reported in China. This large patient population underscores the urgent need for effective treatment options.
Introducing GTX-104 and Its Advantages
GTX-104 leverages advanced nanoparticle technology to create an aqueous formulation of nimodipine suitable for intravenous infusion. This development is particularly important in intensive care settings, as it offers a straightforward intravenous delivery alternative. For patients who are unconscious or have difficulty swallowing, GTX-104 may eliminate the need for a nasogastric tube, thereby enhancing both comfort and treatment effectiveness.
Additionally, the intravenous formulation of GTX-104 minimizes complications often associated with oral medications, such as food interactions and the risk of dosing errors, while improving management for hypotension. Clinical trials have indicated that GTX-104 is well-tolerated, having been administered to over 150 healthy volunteers with positive results.
Broad Market Potential
The market prospect for GTX-104 in the U.S. is projected to reach around $300 million, highlighting its potential as a credible treatment option for patients suffering from aSAH.
Other Ongoing Development Candidates
In addition to GTX-104, Acasti is also focusing on GTX-102 and GTX-101. GTX-102 is an oral-mucosal spray of betamethasone that aims to enhance neurological symptoms in individuals with Ataxia-Telangiectasia. While the current focus is on GTX-104, Acasti may consider licensing or selling GTX-102 down the line.
Conversely, GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine designed to alleviate symptoms of postherpetic neuralgia (PHN). With a non-narcotic formulation, GTX-101 offers a non-invasive application method that could provide rapid pain relief without the side effects common with traditional oral medications.
About Acasti Pharma
Acasti is a leader in biopharmaceutical innovation, targeting rare diseases through its unique drug delivery technologies. The company focuses on enhancing the efficacy and safety profiles of existing treatments, aiming to provide rapid results and greater convenience for patients. Acasti holds Orphan Drug Designation for its primary clinical assets, which grants seven years of marketing exclusivity following their launch in the U.S.
Frequently Asked Questions
What is GTX-104?
GTX-104 is an injectable formulation of nimodipine developed by Acasti Pharma for intravenous use in patients suffering from aneurysmal subarachnoid hemorrhage.
What are the aims of the STRIVE-ON trial?
The primary goal is to assess the safety of GTX-104 by comparing adverse events and effectiveness with oral nimodipine.
How many patients are participating in the STRIVE-ON trial?
The trial involves 100 patients recruited from approximately 25 hospitals in the United States.
When can we expect results from the STRIVE-ON trial?
The data readout from the STRIVE-ON trial is expected in early 2025.
Why is GTX-104 important?
GTX-104 addresses significant challenges posed by oral nimodipine, particularly in administering the drug to unconscious patients, while also helping to minimize complications like adverse events and dosing mistakes.
